Representative matters include:
- Representing Teva in an ongoing patent infringement litigation against Eli Lilly and Company related to Eli Lilly’s Emgality® (galcanezumab) product for the treatment of migraine.
- Representing Celltrion and Teva in patent infringement litigation brought by Genentech and others under the Biologics Price Competition and Innovation Act (BPCIA) related to Celltrion and Teva’s biosimilar rituximab product, Truxima®. The case settled favorably, allowing Celltrion and Teva to launch the first rituximab biosimilar available in the U.S.
- Representing Spatz in patent infringement action brought by L’Oréal USA, Inc. related to cosmetics.
- Representing AMAG Pharmaceuticals in patent infringement action related to a proposed generic version of Feraheme® (ferumoxytol) for the treatment of iron-deficiency anemia.
- Representing an individual in a patent infringement and unfair competition case related to electrical transmission lines.
- Representing Actavis in a patent infringement action filed by Valeant Pharmaceuticals Int’l and others under the Hatch-Waxman Act relating to Actavis’s filing of an abbreviated new drug application for generic versions of Valeant’s drug UCERIS®.At trial, the Court granted Actavis’s motion for judgment of non-infringement under Rule 52(c), allowing for the launch of a generic version of Uceris®.The Federal Circuit later upheld the trial court’s ruling.
- Representing Teva in Hatch-Waxman patent infringement litigation brought by Genzyme in response to Teva’s filing of an abbreviated new drug application seeking approval to market a generic version of Genzyme’s stem cell mobilizing agent, Mozobil® (plerixafor).
- Representing Lupin in patent infringement litigation under the Hatch-Waxman Act in response to Lupin’s filing of an abbreviated new drug application seeking approval to market a generic version of Senju’s Prolensa® (bromfenac ophthalmic solution) medication.
- Representing Roxane in a patent infringement litigation filed by Prometheus in response to Roxane’s filing of an abbreviated new drug application seeking approval to market a generic version of Prometheus’s IBS treatment drug, Lotronex® (alosetron hydrochloride). After a bench trial, the District Court found in favor of Roxane that Prometheus’s patent was invalid.
Prior to joining Goodwin, Ms. Daughtrey was a Make a Difference Fellow at Brooklyn Legal Services Corporation A in the Individual Housing Unit where she represented tenants and tenant associations in housing litigation and appeals.
During law school, Ms. Daughtrey was a judicial intern to the Honorable Ronald M. Whyte, U.S. District Court for the Northern District of California and as a legal intern with the U.S. Attorney’s Office for the Southern District of California in the Civil Division. She was a member of San Diego Law Review.
Ms. Daughtrey is on the Board of Directors of the Los Angeles Intellectual Property Law Association (LAIPLA), as well as the chairperson of several LAIPLA committees. She is also a planning committee member for the USC IP Law Institute.